RPO LLC’s MoonLake Immunotherapeutics MLTX Stock Holding History

RPO LLC’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,600	Closed	-$135K	–	164
2021 Q4	$135K	Buy	+13,600	New	+$135K	0.04%	129

Other funds holding MLTX

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

RPO LLC's MLTX Position: Q1 2022 in Review

RPO LLC sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 13,600 shares — an estimated $135K sold.

RPO LLC first reported a position in MLTX in Q4 2021 and held it in 1 quarter. The position peaked at $135K in Q4 2021. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

RPO LLC reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
RPO LLC sold 13,600 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $135K.
RPO LLC first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 1 quarter.
RPO LLC's MoonLake Immunotherapeutics position peaked at $135K in Q4 2021.
27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on RPO LLC's 13F filing for Q1 2022, filed 13 May 2022.